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diversity of the health professionals and the basic scenario. The costliest scenarios 
were the one implementing HPV DNA testing which did not provide further partici-
pation despite a high cost and the one based on P4P incentives towards GP, although 
it allows high participation rates. ConClusions: Using a comprehensive BIM, we 
show that full coverage of OS might be the most cost-effective way to implement it, 
although practical and financial issues might favour other scenarios that may be 
more balanced regarding the distribution of costs between stakeholders or may be 
more easily implemented and accepted by health professionals.
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Medicine supply of patients with CML is provided by means of federal state reim-
bursement program (FSRP) of high-cost nosologies and by regional budgets. Now, 
the reimbursement list of high-cost drugs includes only first generation tyros-
ine kinase inhibitor (TKI) – imatinib. However, there is a problem with access of 
patients with CML to second generation TKI because regional budgets are limited. 
Therefore, it’s important to provide pharmacoeconomic assessment of including 
second generation TKI into FSRP.objeCtives: To provide budget impact analysis 
(BIA) of including second generation TKI (nilotinib) into reimbursement list of high-
cost drugs of FSRP for second line treatment of patients with CML. Methods: BIA, 
as a part of this healtheconomic research was developed on the basis of decision 
tree and Markov model.The perspective of the study was FSRP of high-cost drugs, 
so direct costs for imatinib and nilotinib were considered.Real consumption of 
medicine was used.Tender prices of FSRP for imatinib and regional tender prices 
for nilotinib were used. Exchange rate 1Euro = 50Rub. Results: Annual cost per 
patient for imatinib for the first line CML patient in chronic phase was 6336Euro, 
while patients in accelerated phase and the second line treatment patients needed 
high dose imatinib treatment that costs 12672Euro.Annual cost per patient for 
nilotinib was 35040Euro.Total expenditures for first line treatment of CML with 
imatinib and the second line treatment with nilotinib for all CML patients were 
82,2 mln Euro.FSRP budget for CML in 2014 was 46 mln Euro, regional expenditures 
for the second line treatment with second generation TI of CML were above 44 
mln Euro.Therefore, including of nilotinib into FSRP leads to budget increase, but 
doesn’t exceed total current expenditures for CML of 90 mln Euro. ConClusions: 
Inclusion of nilotinib into FSRP does not exceed total current expenditures for CML 
and may improve patient access for effective treatment.
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objeCtives: The aim of the study was to conduct a health economic evaluation 
of using everolimus and axitinib in patients with metastatic renal cell carcinoma 
(mRCC). Methods: Cost-effectiveness analysis, budget impact analysis and sensi-
tivity analysis were performed. Progression-free survival and overall survival were 
included into the model as the effectiveness criteria. Decision tree model with Markov 
cycles was used. All direct costs were calculated from the healthcare system perspec-
tive. Stability of results to changes of external factors was evaluated by performing a 
probabilistic sensitivity analysis. Results: An analysis showed that the use of everoli-
mus was by 35% less expensive than the use of axitinib. At the same time a decrease in 
the probability of adverse event occurrence for everolimus, as well as an increase in the 
duration of overall survival by 27% were observed. The total cost per patient amounted 
to 1,686,463 RUB and 2,283,237 RUB when using everolimus and axitinib respectively. 
Compared to axitinib therapy, everolimus therapy is less expensive and at the same 
time, is more effective, i.e. it is dominant in relation to axitinib when considering such 
effectiveness criteria as overall survival and progression-free survival. The results of 
sensitivity analysis confirmed results of the baseline scenario regarding the economic 
feasibility of everolimus usage. The results of the budget impact analysis showed 
potential savings of budget finance in case of using everolimus, which provides an 
opportunity to treat additional patients with mRCC with no additional expenditures on 
the part of health care system. ConClusions: Everolimus showed a longer duration 
of overall survival in patients with mRCC after ineffectiveness of the first-line therapy. 
Moreover, everolimus therapy was less costly compared to axitinib therapy. Thus, the 
results of the study showed that the use of everolimus is a cost-effective strategy, as 
it is characterized by greater efficiency and lower costs.
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objeCtives: To compare cost of rituximab both Intravascular and subcutaneous for 
the treatment of NHL in patients within the social security and retiree segment And 
leaving in rural areas of ARGENTINA. Methods: Insurance given by two main sec-
tors were analysed. IOMA covers 157.741 beneficiaries while PAMI covers 215.118 . 1st 
line and 2nd line full treatments were calculated. As RTX cost is equivalent between 
formulations, we calculated the modules of the treatment including medical fee, 
materials etc. taking into account the IOMA value of USD 140.20 and PAMI one of 
USD 127.12 and the time of treatment in minutes we estimate the savings with the 
SC formulation. Results: IOMA Cost taking into account the consumption of time 
is around USD 1.190, 78 for the first line treatment and USD 899, 66 for the second 
as a second line treatment without increase of the total national CML budget 
in 2014.
PCN70
radIo-223 IN the treatmeNt of metastatIC CastratIoN resIstaNt 
Prostate CaNCer wIth BoNe metastases: Budget ImPaCt aNalysIs of 
the NatIoNal health servICe
Di Matteo S1, Valentino MC1, Bruno GM1, Colombo GL2
1S.A.V.E. Studi - Health Economics & Outcomes Research, Milan, Italy, 2University of Pavia, Milan, 
Italy
objeCtives: Castration resistant prostate cancer with bone metastases (mCRPC) is a 
common condition associated with high medical and indirect healthcare costs. Purpose 
of this analysis is to estimate the economic consequences of Radio-223 dichloride in the 
treatment of prostate cancer with definition of a Budget Impact Analysis (BIA) from the 
perspective of the National Health Service (NHS). Methods: Budget Impact analysis 
was carried to quantify the impact on the Italian National Health Service, in terms of 
costs of treatment given to the castration resistant prostate cancer (mCRPC), and as a 
result of the introduction of Radio-223 dichloride. In the assessment it was assumed 
that all the formulations present the same effect, ie that they present the same prob-
ability of efficacy in the treatment of metastatic castration resistant prostate cancer. The 
calculated values were applied to a population with mCRPC estimated the first year by 
about 4,009 people. Results: Considering the cost of the drug, the costs of administra-
tion, the cost of each adverse event, the total costs of each therapy, Radio-223 dichloride 
appears to have a lower cost than Abiraterone in both setting of patients in the first 
and second line treatment, lower than Enzalutamide in post-docetaxel population. The 
total costs were as follows: Radio-223 dichloride € 24,662.13; Abiraterone pre-Docetaxel € 
54,112.25, € 28,490.63 Abitaterone post-docetaxel, Cabazitaxel € 26,995.20, Enzalutamide 
€ 30,885.55 and finally Docetaxel € 4,574.69. Overall, looking at the scenario of the 1st 
and 2nd line following the introduction of Radio-223 dichloride it would generate sav-
ings of € 1,467,994 the first year, € 3,545,090 in the second year and finally € 7,660,642 in 
the third year. ConClusions: Treatment with Radio-223 dichloride turns out to have 
a favorable impact on the budget and appears to be the less expensive compared to 
other therapeutic strategies used in mCRPC in Italy.
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objeCtives: To determine the avoided cost derived from the opportune interven-
tion of the pharmacist before to the administration of schemes of chemotherapy 
avoiding medication errors (EM). Methods: A transverse analysis of EM’s record 
was realized (classification in accordance with Otero et al., 2000) in solid tumors, 
that evaluate the Clinical Pharmacy Service (CPS), in a period from November 2014 
to April 2015. The intention was to identify the cases of afebrile neutropenia (AN) 
before the application of the scheme of chemotherapy. The cost that had been gen-
erated by the handling of an uncomplicated febrile neutropenia were estimated, 
in accordance with the international recommendations of clinical practice, direct 
medical costs were considered: medicines (institutional catalog of prices), medical 
consultation, laboratory study and hospitalization from Official Federation Journal 
and groups related to the diagnosis IMSS 2015. Results: It was identified a whole 
of 365 (30 %) EM of 1195 pharmacotherapy follow-up, We found 22 patients who had 
AN, with an age average of 52 years, of which 54 % were women, this means 8% of 
total medication errors; 100 % of these errors of this patients group was a category 
“B” the error did not get the patient. The saving by the pharmaceutical interven-
tions was estimated in $80,228(USD), minus the cost of the prophylactic treatment 
after intervention ($13,624). The whole saving was $66,604, so that monthly average 
cost saved by CPS was of $11,101; there are 6 clinical pharmacists, that individu-
ally saved $1,850 monthly. The patients were rescheduled for their application of 
chemotherapy until cure the neutropenia, a prophylaxis was given for the subse-
quent cycles. ConClusions: The opportune intervention of the pharmacist in the 
identification and resolution of medication errors not only represents a clinical 
benefit in the safety of the patient, also is a monetary saving to the institution.
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objeCtives: Accordingly to the third Cancer plan, organized screening (OS) of cervical 
cancer among women aged 25-65 should be implemented in the forthcoming years in 
France. The most cost-effective way to implement OS in the French health care system 
in regard of this objective is yet to be determined. Methods: A budget impact model 
(BIM) was developed in collaboration with the French National Institute of Cancer 
(INCa) and an expert board involving clinical experts and stakeholder representa-
tives (social security, ministry of health, patients and professionals). Time horizon of 
the analysis is three years. Five plausible scenarios aimed towards the whole non-
participating population were assessed in the model. Those were derived from a 
basic scenario consisting of a mailed invitation followed by a mailed recall to which 
were added HPV DNA testing for women over 35, self-sampling kits sent to women 
over 35, pay for performance (P4P) incentives allocated to general practitioners (GP) 
whose eligible patients become participant, diversification of health professionals 
performing the sampling and full coverage of the screening by the statutory health 
insurance. Results: The “full coverage scenario” is the most cost-effective, followed 
by the scenario with self-sampling kits sent to women, the scenario with increased 
